Assignee
SUNESIS PHARMACEUTICALS INC
US·33 granted patents·28 pending applications·524 citations·filing 1998–2020
Top patents by PatentIndex Score
61 records- 0197US7314938B2Modulators of cellular adhesionSUNESIS PHARMACEUTICALS INC·Filed 2004·Granted Jan 1, 2008·86 cites·62 claims
- 0294US7115652B2Aspartyl protease inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2003·Granted Oct 3, 2006·42 cites·29 claims
- 0392US7968565B2Therapeutic combinations comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acidSUNESIS PHARMACEUTICALS INC·Filed 2005·Granted Jun 28, 2011·33 cites·1 claims
- 0492US7132568B2Aspartyl protease inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2003·Granted Nov 7, 2006·34 cites·48 claims
- 0591US6335155B1Methods for rapidly identifying small organic molecule ligands for binding to biological target moleculesSUNESIS PHARMACEUTICALS INC·Filed 1998·Granted Jan 1, 2002·92 cites·14 claims
- 0690US7989468B2Methods of using SNS-595SUNESIS PHARMACEUTICALS INC·Filed 2005·Granted Aug 2, 2011·13 cites·43 claims
- 0790US7202033B2Identification of kinase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2003·Granted Apr 10, 2007·70 cites·30 claims
- 0889US6878743B2Small molecule inhibitors of caspasesSUNESIS PHARMACEUTICALS INC·Filed 2002·Granted Apr 12, 2005·38 cites·43 claims
- 0986US6806279B2Small-molecule inhibitors of interleukin-2SUNESIS PHARMACEUTICALS INC·Filed 2001·Granted Oct 19, 2004·23 cites·19 claims
- 1084US10618887B2Pyrimidinyl tyrosine kinase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2018·Granted Apr 14, 2020·3 cites·17 claims
- 1184US8822493B2SNS-595 and methods of using the sameSUNESIS PHARMACEUTICALS INC·Filed 2013·Granted Sep 2, 2014·5 cites·11 claims
- 1282US10577374B2Bruton's tyrosine kinase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2017·Granted Mar 3, 2020·2 cites·18 claims
- 1381US6143776ATosylproline analogs as thymidylate synthase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2000·Granted Nov 7, 2000·12 cites·20 claims
- 1480US10030016B2Heterocyclic compounds useful as PDK1 inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2015·Granted Jul 24, 2018·2 cites·16 claims
- 1579US6784205B2Compounds that modulate the activity of PTP-1B and TC-PTPSUNESIS PHARMACEUTICALS INC·Filed 2003·Granted Aug 31, 2004·12 cites·24 claims
- 1677US6998233B2Methods for ligand discoverySUNESIS PHARMACEUTICALS INC·Filed 2002·Granted Feb 14, 2006·8 cites·12 claims
- 1777US6919178B2Extended tethering approach for rapid identification of ligandsSUNESIS PHARMACEUTICALS INC·Filed 2001·Granted Jul 19, 2005·14 cites·27 claims
- 1877US6376524B1Triphenyl compounds as interleukin-4 antagonistsSUNESIS PHARMACEUTICALS INC·Filed 2000·Granted Apr 23, 2002·14 cites·15 claims
- 1974US9980949B2SNS-595 and methods of using the sameSUNESIS PHARMACEUTICALS INC·Filed 2014·Granted May 29, 2018·1 cites·7 claims
- 2074US7601725B2Thienopyrimidines useful as Aurora kinase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2005·Granted Oct 13, 2009·3 cites·21 claims
- 2174US6811966B2Methods for rapidly identifying small organic molecule ligands for binding to biological target moleculesSUNESIS PHARMACEUTICALS INC·Filed 2002·Granted Nov 2, 2004·8 cites·16 claims
- 2273US9724338B2Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disordersSUNESIS PHARMACEUTICALS INC·Filed 2014·Granted Aug 8, 2017·1 cites·6 claims
- 2370US2021070752A1Heterocyclic compounds useful as pdk1 inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2470US2020399283A1Bruton's tyrosine kinase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2570US2015150858A1Compounds and compositions for treatment of cancerSUNESIS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2668US11174243B2Succinate forms and compositions of Bruton's tyrosine kinase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2017·Granted Nov 16, 2021·3 cites·19 claims
- 2768US2021017155A1Pyrimidinyl tyrosine kinase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2867US2019175589A1Pharmaceutical formulations, processes for preparation, and methods of useSUNESIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2966US2011008371A1Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disordersSUNESIS PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 3066US2018316309A1Sns-595 and methods of using the sameSUNESIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3165US7214487B2Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidatesSUNESIS PHARMACEUTICALS INC·Filed 2003·Granted May 8, 2007·5 cites·19 claims
- 3265US2020390764A1Pharmaceutical formulations, processes for preparation, and methods of useSUNESIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3364US2014378505A1Sns-595 and methods of using the sameSUNESIS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3463US2019119268A1Heterocyclic compounds useful as pdk1 inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3562US9873693B2Methods of treatment using pyridinonyl PDK1 inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2014·Granted Jan 23, 2018·0 cites·15 claims
- 3662US9757363B2SNS-595 and methods of using the sameSUNESIS PHARMACEUTICALS INC·Filed 2016·Granted Sep 12, 2017·0 cites·17 claims
- 3761US9676774B2Compounds and compositions for treatment of cancerSUNESIS PHARMACEUTICALS INC·Filed 2016·Granted Jun 13, 2017·0 cites·6 claims
- 3861US9469635B2Stable SNS-595 compositions and methods of preparationSUNESIS PHARMACEUTICALS INC·Filed 2013·Granted Oct 18, 2016·0 cites·16 claims
- 3961US2010022399A1Methods for rapidly identifying small organic molecule ligands for binding to biological target moleculesSUNESIS PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 4061US2014179542A1Methods for rapidly identifying small organic molecule ligands for binding to biological target moleculesSUNESIS PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 4160US2019084978A1Stable sns-595 compositions and methods of preparationSUNESIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4260US2018370966A1Methods of treatment using pyridinonyl pdk1 inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4359US9969730B2Stable SNS-595 compositions and methods of preparationSUNESIS PHARMACEUTICALS INC·Filed 2016·Granted May 15, 2018·0 cites·9 claims
- 4457US2011263524A1Sns-595 and methods of using the sameSUNESIS PHARMACEUTICALS INC·Filed 2011·Application pending·0 cites
- 4556US2010179123A1Thienopyrimidines useful as aurora kinase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 4656US2015157614A1Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acidSUNESIS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4755US8802719B2Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acidSUNESIS PHARMACEUTICALS INC·Filed 2013·Granted Aug 12, 2014·0 cites·1 claims
- 4854US2007026451A1Methods for rapidly identifying small organic molecule ligands for binding to biological target moleculesSUNESIS PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 4954US2015190380A1Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disordersSUNESIS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 5054US2014205679A1Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapySUNESIS PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
Showing the top 50 of 61 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when SUNESIS PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →